Show simple item record

dc.contributor.authorPiperdi, May
dc.contributor.authorMcDade, Theodore P.
dc.contributor.authorShim, Joon K.
dc.contributor.authorPiperdi, Bilal
dc.contributor.authorKadish, Sidney P.
dc.contributor.authorSullivan, Mary E.
dc.contributor.authorWhalen, Giles F.
dc.contributor.authorTseng, Jennifer F.
dc.date2022-08-11T08:10:59.000
dc.date.accessioned2022-08-23T17:27:14Z
dc.date.available2022-08-23T17:27:14Z
dc.date.issued2010-04-02
dc.date.submitted2011-06-23
dc.identifier.citationHPB (Oxford). 2010 Apr;12(3):204-10. <a href="http://dx.doi.org/10.1111/j.1477-2574.2009.00150.x">Link to article on publisher's site</a>
dc.identifier.issn1365-182X (Linking)
dc.identifier.doi10.1111/j.1477-2574.2009.00150.x
dc.identifier.pmid20590888
dc.identifier.urihttp://hdl.handle.net/20.500.14038/49818
dc.description.abstractBACKGROUND: Recent studies have shown adjuvant therapy improves outcomes from pancreatic cancer (PC). This study investigates receipt and timing of PC treatments, and association with outcomes. METHODS: The analysis cohort consisted of patients with newly-diagnosed PC at a single institution over 5 years. Primary Endpoints were (i) receipt of recommended therapy, and (ii) overall survival (OS). RESULTS: Among 102 patients, 52 underwent resection. Out of 36 localized resected and 16 locally advanced resected (LAR) patients, 26 and 13, respectively, received adjuvant therapy. Six of the latter group received neoadjuvant therapy. Median OS for resected patients was 15.7 months (range 0.6-51.4), compared with 7.7 for unresected patients (range 0.4-32.0) (P < 0.001), and 14.0 months for patients with resection alone (range 0.6-24.4) vs. 16.1 for patients who also received adjuvant therapy (range 3.2-51.4) (P= 0.027). Out of 46 patients undergoing up-front resection, 33 had R0 surgical margins. For the six LAR patients undergoing neoadjuvant therapy, all margins were R0. CONCLUSION: After resection, a substantial proportion of patients do not receive adjuvant therapy, and have worse survival. In this study, neoadjuvant treatment increased both the proportion of patients receiving all components of recommended therapy and the R0 resection rate.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=20590888&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889273/pdf/hpb0012-0204.pdf
dc.subjectAdenocarcinoma
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAntibodies, Monoclonal
dc.subjectAntineoplastic Agents
dc.subjectChemotherapy, Adjuvant
dc.subjectCohort Studies
dc.subjectDeoxycytidine
dc.subjectFemale
dc.subjectFluorouracil
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subject*Neoadjuvant Therapy
dc.subjectPancreatectomy
dc.subjectPancreatic Neoplasms
dc.subjectPancreaticoduodenectomy
dc.subjectPostoperative Complications
dc.subjectRadiotherapy, Adjuvant
dc.subjectSurgery
dc.titleA neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database
dc.typeJournal Article
dc.source.journaltitleHPB : the official journal of the International Hepato Pancreato Biliary Association
dc.source.volume12
dc.source.issue3
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/surgery_pp/95
dc.identifier.contextkey2073453
html.description.abstract<p>BACKGROUND: Recent studies have shown adjuvant therapy improves outcomes from pancreatic cancer (PC). This study investigates receipt and timing of PC treatments, and association with outcomes.</p> <p>METHODS: The analysis cohort consisted of patients with newly-diagnosed PC at a single institution over 5 years. Primary Endpoints were (i) receipt of recommended therapy, and (ii) overall survival (OS).</p> <p>RESULTS: Among 102 patients, 52 underwent resection. Out of 36 localized resected and 16 locally advanced resected (LAR) patients, 26 and 13, respectively, received adjuvant therapy. Six of the latter group received neoadjuvant therapy. Median OS for resected patients was 15.7 months (range 0.6-51.4), compared with 7.7 for unresected patients (range 0.4-32.0) (P < 0.001), and 14.0 months for patients with resection alone (range 0.6-24.4) vs. 16.1 for patients who also received adjuvant therapy (range 3.2-51.4) (P= 0.027). Out of 46 patients undergoing up-front resection, 33 had R0 surgical margins. For the six LAR patients undergoing neoadjuvant therapy, all margins were R0.</p> <p>CONCLUSION: After resection, a substantial proportion of patients do not receive adjuvant therapy, and have worse survival. In this study, neoadjuvant treatment increased both the proportion of patients receiving all components of recommended therapy and the R0 resection rate.</p>
dc.identifier.submissionpathsurgery_pp/95
dc.contributor.departmentDepartment of Surgery
dc.source.pages204-10


This item appears in the following Collection(s)

Show simple item record